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Abstract
Pax3 is an essential paired- and homeodomain-containing transcription factor that is necessary for closure of the neural tube, and morphogenesis
of the migratory neural crest and myoblast lineages. Homozygous loss-of-function mutation results in mid-gestational lethality with defects in
myogenesis, neural tube closure and neural crest-derived lineages including melanocytes, Schwann cells and insufficient mesenchymal cells to
septate the cardiac outflow tract. To address the function of Pax3 in later fetal stages and in specific adult tissues, we generated a floxed Pax3 allele
(Pax3flox). An intermediate allele (Pax3neo) was produced via creation of the floxed allele, in which the TK-neo(R) cassette is present between exons
5 and 6. It was deduced to be a hypomorph, as Pax3 protein expression is reduced by 80% and homozygote hypomorphs die postnatally. To assess
the consequences of reduced Pax3 levels on the various Pax3-expressing lineages and to determine the underlying cause of lethality, we examined
Pax3 spatiotemporal expression and the resultant defects. Defective limb and tongue musculature were observed and lethality was due to an inability
to suckle. However, the heart, diaphragm, trunk musculature, as well as the various neural crest-derived lineages and neural tube were all unaffected
by reduced Pax3 levels. Significantly, elevated levels of the related Pax7 protein were present in unaffected neural tube and epaxial somatic
component. The limb and tongue myogenic defects were found to be due to a significant increase in apoptosis within the somites that leads to a
paucity of migratory hypaxial myoblasts. These effects were attributed to the hypomorphic effect of the Pax3neo allele, as removal of the TK-neo(R)
cassette completely relieves the hypomorphic effect, as 100% of the Pax3flox/flox mice were normal. These data demonstrate a lineage-specific
response to∼80% loss of Pax3 protein expression, with myogenesis of limb and tongue being most sensitive to reduced Pax3 levels. Thus, we have
established that there are different minimum threshold requirements for Pax3 within different Pax3-expressing lineages.
© 2008 Elsevier Inc. All rights reserved.Keywords: Mouse embryo; Somites; Pax3; Hypomorph/gene dosage; Tongue and limb hypaxial muscle; Apoptosis; Pax7Introduction
Pax (paired-box) factors are a highly conserved family of
transcription factors belonging to the helix–turn–helix class.
They are characterized by the presence of a paired-domain (a
bipartite DNA binding domain) and are often associated with a
homeodomain which itself is able to form both homo- and
hetero-dimers on DNA (Jun and Desplan, 1996). There are nine
mammalian Pax genes that are expressed early during em-
bryogenesis and guide development by promoting cell-lineage
specification, as well as cell survival, proliferation and migra-
tion. Their expression is spatiotemporally restricted during⁎ Corresponding author. Riley Hospital for Children, 1044 West Walnut
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doi:10.1016/j.ydbio.2007.12.020development, and homozygous mutations in most of them result
in specific developmental defects (Mansouri et al., 1999; Chi
and Epstein, 2002). An intriguing feature of this family is that
many Pax genes exhibit an unusual gene dosage requirement.
Loss-of-function heterozygous mutations in Pax1, Pax2, Pax3,
Pax6, Pax8 and Pax9 each cause semi-dominant phenotypes in
either the mouse or human, or both (Epstein et al., 1991;
Baldwin et al., 1992; Hanson et al., 1994; Keller et al., 1994;
Sanyanusin et al., 1995; Macchia et al., 1998; Wilm et al., 1998;
Stockton et al., 2000; van Raamsdonk and Tilghman, 2000; Kist
et al., 2005). Usually the affected tissue in heterozygous mu-
tants is reduced in size, and either more severely disrupted or
missing in homozygotes (van Raamsdonk and Tilghman, 2000).
Similarly, sensitivity to Pax dosage is also evident from trans-
genic over-expression of Pax2 and Pax6 (Dressler et al., 1993;
Schedl et al., 1996; Kim and Lauderdale, 2006). Remarkably,
transgenic mice that over-express Pax6 exhibit a phenotype
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Pax6 mutants (Hill and Van Heyningen, 1992).
Although the molecular basis for the Pax gene dosage
requirement is not known, it has generally been assumed that
the protein products act within a concentration range sensitive to
twofold changes. This may in turn result in prolonged times to
reach required Pax factor threshold leading to developmental
delays (van Raamsdonk and Tilghman, 2000). Alternatively,
based on the monoallelic expression of Pax5 (Nutt et al., 1999)
and the reduced size of affected tissues in the heterozygous
mutants, it has been suggested that haplo-insufficiency could be
explained if heterozygous cells activate either the wild-type or
mutant allele, but not both (Nutt and Busslinger, 1999). Thus, a
heterogeneous population of both wild-type and null cells could
co-exist in Pax heterozygous animals that results in stochastic
cell fate determination and ultimately smaller Pax-specified
lineages.
PAX3 is expressed in the 8–9 week old human fetus (Terzic
and Saraga-Babiæ, 1999) and from E8 onwards in mice (Goul-
ding et al., 1991). Pax3-deficient mice embryos die in utero and
have multiple defects affecting neural tube (NT) closure, myo-
genesis and morphogenesis of neural crest-derived cells/tissues
including melanocytes, Schwann cells and a subpopulation of
mesenchymal cells in outflow tract. Significantly, Pax3 is a key
regulator of embryonic skeletal muscle formation, as it can
directly regulate Myf5 (which plays a major role in determining
myogenic cell fate at the onset of skeletal muscle formation) in
the hypaxial somite and its derivatives (Bajard et al., 2006).
Along with the related Pax7, it has been shown to be expressed
in skeletal muscle progenitor cells (Relaix et al., 2005). How-
ever, Pax3 may be dispensable for postnatal muscle regenera-
tion since Pax3-postive cells cannot effectively regenerate
muscle in the absence of Pax7 (Kuang et al., 2006). Pax3 null
embryonic muscular defects are thought to result from loss of
Pax3 activation of c-Met tyrosine kinase receptor (Epstein
et al., 1996; Yang et al., 1996; Relaix et al., 2003), which is
essential for the delamination/migration of muscle progenitor
cells (Bladt et al., 1995), while the pigmentary defects are
thought to result from lack of Pax3-regulated Mitf transcription
factor that controls expression of dopachrome tautomerase
expression and melanin synthesis (Lang et al., 2005). Although
the mechanism leading to NT defects is presently unclear, it has
been shown that Pax3 mutant NT defects can either be reduced
by maternal folic acid supplementation (Greene and Copp,
2005) or by placing Pax3 nulls on a p53 null background to
prevent apoptosis and rescue NT closure (Loeken, 2005). The
Pax3 null cardiovascular defects include persistent truncus
arteriosus (PTA) and obligatory interventricular septal defects
(VSDs) due to a dramatic deficiency of cardiac neural crest
(NC) cells (Conway et al., 1997a, 2000; Stoller and Epstein,
2005). Furthermore, Pax3 heterozygotes exhibit pigmentation
defects of varying penetrance depending on genetic back-
ground, indicating that melanocytes are partially sensitive to a
50% reduction in Pax3 gene dosage (Conway et al., 1997b). In
patients, haploinsufficient PAX3 (2q35) mutations manifest as
Waardenburg syndrome I or III and cause developmental ano-
malies of the eyelids, eyebrows and nose root with pigmentarydefects of the iris and head hair with congenital deafness
(Waardenberg, 1951). Interestingly, heterozygous murine Pax3
mutation phenotypes do not include dystopia canthorum or
deafness. Thus, despite the presence of multiple systemic mu-
tant mice lines and extensive patient genotype-phenotype corre-
lations, it is still not known how Pax3 mutations affect tissues
within such a wide range of cell types.
To address these limitations, we have taken advantage of a
novel, hypomorphic Pax3 allele (Pax3neo) and investigated the
developmental consequences of a more drastic Pax3 gene do-
sage reduction. Analyses of these mice revealed that myogen-
esis is the most sensitive developmental process affected by
80% reduction of Pax3 protein. Significantly, myogenesis is not
uniformly affected in all long-range migrating myoblast pre-
cursors giving rise to muscles in different organs. The con-
sequence of reduced gene dosage of Pax3 in hypomorphic
somites is first evident as elevated apoptosis prior to myoblast
migration into the limb and toward the tongue. In addition, we
identified compensatory up-regulation of closely related Pax7 in
Pax3neo/neo mutants, demonstrating genetic redundancy and a
hitherto unappreciated role for Pax7 in NT and NC morphogen-
esis. We propose that the absence of myoblasts in hypomorphic
embryo limbs arise due to lack of cell survival prior to migra-
tion, secondary to a delay in achieving a threshold of Pax3
required for myoblast precursor survival.Materials and methods
Mice colonies and genotyping
Generation of the C57Bl6 Pax3 conditional allele was previously described
(Koushik et al., 2002). Briefly, exon5 was flanked by a 5′ loxP and a 3′ loxP-
flanked thymidine kinase (TK) promoter-driven neomycin cassette—TK-neo
(R) (Fig. 1A). Heterozygous Pax3neo mice are fertile, and mice and embryos
resulting from intercrosses were genotyped by PCR using primers 1,2 spanning
the 5′ loxP site to amplify both the wild-type (315 bp) and Pax3neo (349 bp)
alleles (Fig. 1A).
To selectively remove the floxed TK-neo(R) cassette in the germline, adult
male Pax3neo heterozygous mice were crossed to female C57Bl6 Tie2−Cre (as
Tie2−Cre is expressed in female germ cells; Koni et al., 2001). The resulting
progeny were screened by PCR using primers (1,2) and primers (1,3). With this
screening strategy (Fig. 1), the allele with selective removal of TK-neo (referred
to flox) was identified as containing both the 349 bp (1,2) and 1929 bp (1,3)
bands. The identity of flox allele was further confirmed as negative for neo-
based PCR (data not shown). The primer sequences were as follows: #1 forward
5′-CATTTCTATCTCATTCTCTGGACC-3′; #2 reverse 5′-AAGTCGGAGTC-
TCTGCTGAGG-3′; #3 reverse 5′-GCAGGCAGCAAT-GTTAGCTTAG-3′.
Resultant Pax3flox/+ males were crossed to wild-type C57Bl6 females to remove
Tie2-Cre transgene, and then intercrossed to produce Pax3flox/flox mice. Geno-
typing and breeding of Sp2H mice were as described (Conway et al., 2000). All
breeding colonies were maintained in our animal facility and studies conducted
according to Institutional Animal Care and Use guidelines. For timed
pregnancies, the day of observed vaginal plug was designated embryonic day
0.5 (E0.5).
Reverse transcriptase-PCR and Western blot analysis
Total RNA isolated from individual E10.5 embryos was reverse-transcribed
and RT-PCR analysis for Pax3 and GAPDH was performed as described
(Conway et al., 1997a). RT-PCR was carried out twice in duplicate (n=4). For
Western analysis, individual E10.5 embryos were homogenized in 300 μl
protein lysis buffer (10 mM Tris, pH 6.8, 100 mM NaCl, 10 mM EDTA, 1%
Fig. 1. Characterization of Pax3neo allele. (A) Schematic representation of
targeted Pax3neo allele (Koushik et al., 2002) and PCR genotyping strategy.
Note loxP sites (triangles) flank exon5 of the Pax3 gene and the downstream
neomycin cassette. Arrows indicate location of primers (#1–3) used for PCR
genotyping. Combination of primers 1 and 2 amplifies both the wild-type
(315 bp) and modified (349 bp) allele via the extra 34 bp contributed by the 5′
loxP site. Combination of primer 1 and 3 amplifies wild-type allele (1861 bp)
and neo-removed exon5-floxed allele (1929 bp). Representative PCR with pri-
mer 1 and 2 combination is shown for wild-type (+/+), heterozygote (Pax3+/neo)
and homozygous (Pax3neo/neo). (B) RT-PCR analysis of Pax3 expression levels.
Note that in duplicate E10.5 embryos the level of Pax3 mRNA expression is
reduced in a dose-responsive manner in both the heterozygous and homozygous
embryos, with the most significant decrease within Pax3neo/neo samples
(indicated via *). This is in contrast to the uniform expression of the GAPDH
internal control. (C–E) Western analysis of Pax3 protein expression. (C)
Specificity of the anti-Pax3 antibody was verified via Sp2H/Sp2H and wild-type
littermate E10.5 embryos. Note in Sp2H/Sp2H embryos that ∼53 kDa Pax3 is
absent but actin is expressed at similar levels to control littermates. Using the
same conditions, there is a dose-responsive decrease in Pax3 levels in both the
E10.5 heterozygous (∼40% and small *) and homozygous (∼80% and large *)
Pax3neo whole embryos despite equivalent actin expression levels. (D)
Similarly, there is decrease (∼80%) in Pax3 levels in duplicate E10.5
homozygous Pax3neo isolated heads (*) relative to duplicate heterozygous and
wild-type littermate heads (despite similar actin expression). (E) There is also
reduced Pax3 levels in duplicate E9.0 homozygous Pax3neo whole embryos (*)
compared to duplicate wild-type littermates. Note when the signal intensity was
quantified using ImageJ software, E9.0 Pax3neo/neo embryos only contained
∼20% Pax3 levels when compared to wild-type littermates (normalized to actin
levels).
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(16,000 rpm at 4 °C), the supernatant was transferred to new tube, 60 μl of
6× SDS-PAGE loading buffer added and denatured for 10 min at 94 °C in the
presence of 100 mM β-mecaptoethanol. For each sample, 50 μl was resolved
using 10% SDS-PAGE (Bio-Rad) and transferred to nitrocellulose. Membranes
were blocked for 1 h in 5% non-fat milk (in phosphate buffered saline (PBS)
with 0.5% Tween20) and probed with mouse monoclonal anti-Pax3 (1:2000dilution) or monoclonal anti-Pax7 (1:2000 dilution) antibodies (both obtained
from the Hybridoma Bank) in blocking solution. The signal was revealed via
ECLPlus (Amersham) with peroxidase-conjugated goat anti-mouse secondary
antibody (1:5000 dilution, Promega). To verify equal loading, all blots were
subsequently stripped (0.2 M NaOH for 5 min at room temperature), thoroughly
washed, re-blocked and then probed with mouse anti-actin antibody (1:5000
dilution, Sigma). X-ray films were scanned and signal intensity measured using
ImageJ software (downloaded from wsr@nih.gov).
Histological, in situ hybridization and immunohistochemical analysis
Embryos were fixed in 4% paraformaldehyde at 4 °C overnight and pro-
cessed for routine paraffin sections (10 μm) for histology, in situ hybridization
and/or immunohistochemistry using standard procedures. Embryos older than
E14 were decalcified in 0.5 M EDTA prior to dehydration. For histological
analysis, the sections were stained with hematoxylin/eosin. In situ hybridization
of Pax3, Crabp1, cMet Periostin,MyoD,Myf5,Msx2 and Sox10 was performed
as previously described (Conway, 1996) using S35 or DIG-labeled cRNA
probes. Hybridization with corresponding sense probe was paralleled as a
negative control. Pax3, Crabp1 and Periostin probes have been previously
described (Conway et al., 2000; Kruzynska-Frejtag et al., 2001), while MyoD,
cMet and Myf5 were provided by Dr. Chen-Ming Fan (Chen et al., 2005),
Msx1 and Msx2 by Dr. Robert Maxson (Kwang et al., 2002) and Sox10 was
cloned via PCR amplification of E12.5 whole embryo cDNA using the follow-
ing primers (5′-TCTGTCTTCACCTGGGCTTT and 3′-ATGTCAGATGGGA-
ACCCAGA).
Immunostaining was carried out using ABC kit (Vectorstain) with DAB and
hydrogen peroxide as chromogens. The endogenous peroxidase was quenched
via a 20-min incubation in 0.3% hydrogen peroxide in PBS. For detection of
Pax3 and Pax7, sections were boiled in antigen retrieval buffer (Dako) for 2 min
and then cooled to room temperature prior to blocking. The dilution of primary
antibody was 1:5000 for mouse anti-alpha smooth muscle actin (αSMA;
Sigma), 1:200 for goat anti-Pax3 antibody (Santa Cruz sc-7748) and mouse anti-
Pax7 (Hybridoma Bank). Incubation in primary antibody was carried out at 4 °C
overnight, and incubation in secondary antibody and ABC was performed at
room temperature for 30 min at 1:400 dilution. All washes were carried out in
PBS with 0.5% Tween20 at room temperature. The specificity of Pax3 staining
was confirmed by using age-matched Pax3 null (Sp2H/Sp2H) sections.
Skeletal staining
E17.5 embryos (n=13) were collected in PBS and fixed in 70% ethanol,
30% acetic acid and 0.01% Alcian blue 8GX for 3–5 days. After dehydration to
100% ethanol, embryos were stained with 0.5% KOH+0.01% alizarine S for
10 min. Embryos were then cleared in 1% KOH/20% glycerol and then
dehydrated gradually to 100% glycerol and photographed.
Detection of cell proliferation and apoptosis
Timed pregnant mice were injected with BrdU at recommended dosage
(1 ml/100 g, ZYMED) 2 h prior to sacrifice. Embryos were fixed and processed
for paraffin sections. Incorporated BrdU was detected with ZYMED BrdU
staining kit following the manufacturer’s instruction. TUNEL analysis was
performed on 10 μm paraffin sections using the ApopTag® peroxidase In Situ
Apoptosis Detection Kit (S7100, Chemicon) according to manufacturer’s
directions. Sections were counterstained with methyl green. For both assays,
serial sections were examined using at least three individual E10.5 embryos of
each genotype.Results
The Pax3neo allele is hypomorphic
Mice heterozygous for the Pax3 conditional allele (Pax3neo/+)
(Koushik et al., 2002) are viable and fertile (nN100), and lack
372 H.-M. Zhou et al. / Developmental Biology 315 (2008) 369–382the characteristic white belly spot, a feature of Pax3 loss-of-
function heterozygous mutations (Koushik et al., 2002; Engleka
et al., 2005). However, intercross of Pax3neo/+ failed to produce
any adult homozygous offspring, suggesting that the floxed
allele retaining the TK-neo(R) cassette is not fully functional.
Genotyping of newborns and 3-week old pups from Pax3neo/+
intercrosses reveals that Pax3neo/neo are viable and present at
expected Mendelian ratios at day 1 after birth but not at day 21.
In contrast, mice homozygous for loss-of-function mutation
(Sp2H) alleles die ∼E14 at mid-gestation (Epstein et al., 1996;
Conway et al., 1997c). The postnatal death of Pax3neo/neo
neonates suggests the Pax3neo allele is a hypomorph.
To determine the extent of the hypomorphic effect, we first
checked Pax3 mRNA expression levels using RT-PCR. Pax3
expression was detected in all three genotypes but was sig-
nificantly reduced in Pax3neo homozygote (∼20%) E10.5 em-
bryos (Fig. 1B). We chose to examine Pax3 expression at E10.5
as this was 2 days prior to any morphological alterations being
evident (Fig. 2). Additionally, a larger transcript containing
neomycin was amplified in Pax3neo heterozygote and homo-Fig. 2. Reduced Pax3 levels result in disorganization of Pax3neo/neo tongue muscula
radioactive in situ hybridization of Pax3 and early (Myf5) and late (MyoD) muscle ma
anomalies at day 1 (A, B), E15.5 (C–J) and E12.5 (K–M). Day-1 sagittal sections sta
thinner (red lines indicates the position of tongue tips) than in wild-type (A). (C and
Note that E15.5 Pax3neo/neo tongue musculature was greatly reduced and disorganized
disorganized αSMA-expressing cells on adjacent sections (C and G). The arrow in pa
is already evident at this stage. (K–M) αSMA staining of sagittal E12.5 wild-type (K
absent while extrinsic (EX) muscles are intact in Pax3neo/neo. However, both intrins
muscles affected in E12.5 Pax3 mutants.zygote samples (data not shown). Given that the TK-neo(R)
cassette may interfere with gene expression (Meyers et al.,
1998; Nagy et al., 1998), we sequenced RT-PCR products and
confirmed neomycin insertion in the intron generates alterna-
tively spliced Pax3 mRNA forms resulting in reduced Pax3
levels (data not shown). Next we examined Pax3 protein levels
via Western analysis using a mouse anti-Pax3 monoclonal
antibody that recognizes the Pax3 C-terminus which is absent in
Sp2H/Sp2H embryos due to premature stop codon and predicted
truncated protein (Epstein et al., 1991). The specificity of the
assay was verified using E10.5 Sp2H/Sp2H embryos as a nega-
tive control, that lack the ∼53 kDa Pax3 peptide (Fig. 1C). In
line with RT-PCR data, a ∼53 kDa Pax3 band was detected in
all three genotypes, with signal intensity being weakest in
Pax3neo/neo embryos. Band intensity was scanned and quanti-
fied using ImageJ software. Relative to wild-type littermates,
the protein level was ∼60% in Pax3neo/+ and only ∼20% in
Pax3neo/neo (Fig. 1C). Given that Pax3 is predominantly
expressed in neural tube, somites and migratory myoblast
lineages at E10.5 and that subsequent analysis revealed a lack ofture. Both immunohistochemistry for alpha smooth muscle actin (αSMA) and
rker expression were used to assess muscle deficiencies and pathogenesis of the
ined for αSMA expression indicate that the Pax3neo/neo (B) tongue is shorter and
G) αSMA staining in E15.5 wild-type (C) and Pax3neo/neo (G) sagittal sections.
. Pax3 (D, H),Myf5 (E, I) andMyoD (F, J) mRNA expression patterns mirror the
nel G points to location of tongue tip in Pax3neo/neo. Note that the shorter tongue
), Pax3neo/neo (L) and Sp2H/Sp2H (M) sections. Intrinsic (IN) muscles are partially
ic and extrinsic Sp2H/Sp2H tongue muscles are absent. Arrow indicates intrinsic
373H.-M. Zhou et al. / Developmental Biology 315 (2008) 369–382migratory myoblasts in the Pax3neo/neo limb buds (Figs. 4 and
6), we measured Pax3 protein levels via Western analysis in
isolated E10.5 heads (to examine whether reduced levels were
due to tissue loss or global down-regulation within Pax3-ex-
pressing lineages). Similarly, Pax3 levels were ∼60% in
Pax3neo/+ and only ∼20% in Pax3neo/neo heads/neural tissues
when compared to actin (Fig. 1D). Finally, as there would be
significantly fewer migratory limb myoblasts at E9.5 as
migration is just initiating, we examined E9.5 embryos for
Pax3 protein levels. Consistent with aforementioned Western
data, Pax3 levels were ∼20% in E9.5 Pax3neo/neo embryos
relative to wild-type littermates (+/+=128,327±20,226 and
neo/neo=23,346±1275 n=3 Westerns of duplicate samples)
(Fig. 1E). Thus a Pax3neo hypomorphic allele encodes ∼10%
Pax3 protein relative to ∼50% encoded by a wild-type allele,
and Pax3 expression levels are reduced in all tissues examined.
These global Pax3 suppression data are consistent with later
Pax3 immunohistochemistry data (Fig. 6). Furthermore, the
lack of white belly spots in Pax3neo/+ adult mice (nN100) indi-
cates that ∼60% Pax3 protein (i.e. 10% from Pax3neo allele+
50% from wild-type allele) is sufficient to initiate/maintain
normal pigmentation. Taken together, these results indicate theFig. 3. Reduced Pax3 levels result in severe limb musculature anomalies. (A) Pax3neo/
undersized and severely dysmorphic limbs (# indicate Pax3neo/neowarped forelimbs) a
expression in the E15.5 wild-type (B, D) and Pax3neo/neo (C, E) forelimbs at the level
via * in panels D, E) bones. Note that most of theMyoD-positive muscle masses are a
as a reference to show comparable section levels. (F, G) Immunostaining for αSMA
E13.5 forelimbs and hindlimbs. Note Pax3neo/neo embryos are already abnormal at
severely hypoplastic (hindlimbs) or completely missing (forelimbs) in hypomorphicPax3neo allele is hypomorphic, encoding ∼20% level of wild-
type allele expression and consequently is not compatible with
postnatal survival.
Neonatal lethality of Pax3neo/neo pups
Screening of 120 pups collected shortly after delivery in-
dicates that Pax3neo/neo mice were born alive in an expected
Mendelian ratio (data not shown). Characteristically, all
Pax3neo/neo neonatal mice had dysmorphic limbs with forelimbs
being more obviously affected than hindlimbs (Fig. 3A). Having
established the fully penetrant dysmorphic phenotype, we
carefully examined mice upon delivery. Newborn Pax3neo/neo
pups were comparable in body size and appearance (except for
the limb defects and absence of milk in their stomachs). This
suggested that subsequent growth retardation (noticeable by day
2) was postnatal, and that respiration and circulation were not
compromised by reduced Pax3 levels. This is consistent with
subsequent analysis of cardiovascular system (Supplemental
Fig. 1) and lungs/diaphragm (Supplemental Fig. 2), demonstrat-
ing normal cardio-pulmonary vascular morphogenesis. The
Pax3neo/neo pups all died by day 3, and progressive growthneo day-2 pups are readily distinguished from their wild-type (+/+) littermates via
nd lack of ingested milk (asterisk). (B–E) In situ hybridization analysis ofMyoD
of the ulnar (u)/radius (r) (indicated via * in panels B, C) and phalange (indicated
bsent within the hypomorphic forelimbs. The asterisks indicate the bones serving
at various medial-lateral section levels along wild-type (F) and Pax3neo/neo (G)
this early developmental stage and αSMA-positive muscle masses are either
embryos. Abbreviations: f, fibula; t, tibia.
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absence of ingested milk and any sucking behavior in
homozygous Pax3neo pups (nN30). The lack of ingested milk
was further confirmed by direct histological examination (data
not shown). The lumen of the stomach of wild-type pups was
stretched and full of acellular protein aggregates (eosinic-
positive and hematoxylin-negative), indicative of proteins from
ingested milk. However, the Pax3neo/neo lumen was empty and
the stomach wall thin and tightly folded due to a lack of ex-
pansion. This analysis indicates that Pax3neo/neo pups were
viable at birth but were unable to feed.
Given the potential effects of the TK-neo(R) cassette, we next
crossed heterozygous Pax3neo animals with mice expressing Cre
recombinase to delete the loxP-flanked sequences. Taking
advantage of known Cre expression in Tie2-Cre transgenic
oocytes (Koni et al., 2001), we crossed adult male Pax3neo/+
with female Tie2-Cre mice. The Cre activity present in fertilized
oocytes mediated three possible recombination events and gave
rise to chimeric progeny with more than one recombined allele.
Using PCR screening and intercrossing with wild-type C57Bl6
mice, we identified mice that had deleted the floxed TK-neo(R)
cassette but retained the loxP flanked exon5 (termed Pax3flox).
Intercross of Pax3flox/+ mice demonstrated that Pax3flox homo-
zygotes reach adulthood (n=24/24 indicates 100% survival)
with a normal Mendelian frequency (data not shown) and repro-
duce normally, thus deletion of TK-neo(R) cassette fully restores
viability and prevents the hypomorphic effects. Furthermore,
Western analysis of E10.5 Pax3flox/flox embryos revealed same
Pax3 levels when compared with wild-type littermates (data not
shown), indicating that remaining two loxP sites flanking exon5
have no impact on Pax3 expression. Thus, the hypomorphic
effect and lethality is solely attributed to the presence of TK-neo
(R) cassette, and not any unintended potential mutational effects
due to insertion of loxP sites in introns.
Reduced Pax3 levels result in lack of tongue musculature
Having observed the absence of milk in the stomachs of
newborn Pax3neo/neo, we were prompted to investigate if tongue
development might have been impaired due to Pax3 reduction.
Following this hypothesis, we examined Pax3neo/neo tongues in
day 1, E15.5 and E12.5 animals using αSMA immunohisto-
chemistry and Pax3, Myf5 (an early myogenic determination
factor) andMyoD (a later myogenic factor) in situ hybridization
analysis. In newborns, αSMA expression was present in both
wild-type and Pax3neo/neo tongues; however, there was a
striking difference in the extent of αSMA-positive cells, their
organization and the size of the tongue (Figs. 2A, B). In control
littermates, the tongue was longer, reaching the mouth opening.
In Pax3neo/neo, the newborn tongue tip merely reached halfway
and was also significantly thinner. This anatomical defect would
adversely impact suckling, which demands an intimate contact
between tongue tip and nipple.
Although tongue thickness was comparable between wild-
type and Pax3neo/neo at E15.5, it was already evident that the
Pax3neo/neo tongue was shorter and αSMA-positive cells se-
verely disorganized (Fig. 2G). The transcripts of Pax3, Myf5and MyoD were each detectable in both E15.5 wild-type and
Pax3neo/neo, tongues. However, while expression in wild-type
was restricted to the front half of tongue and present in regularly
aligned myoblasts that correspond to the intrinsic muscles
(superior longitudinal, transverse and vertical components) and
underlying extrinsic muscles (longitudinal genioglossus, hyo-
glossus and styloglossus), expression in Pax3neo/neo was
diminished and exhibited an irregular organization (Fig. 2). At
E12.5, while the thickness was comparable between Pax3neo/neo
and control tongues, the reduced length was just becoming
evident (Fig. 2L). Significantly, αSMA staining revealed that
the intrinsic superior longitudinal muscle layer is almost com-
pletely absent and the vertical components of the intrinsic
muscles are disorganized and/or absent from the hypomorphic
tongue tip. In order to compare the severity of these muscular
defects with embryos that completely lack functional Pax3
protein, we assessed αSMA in Sp2H/Sp2H E12.5 embryos (Fig.
2M). As expected, the phenotype is more severe and the entire
tongue was mostly devoid of αSMA-expressing cells. This
more severe Sp2H/Sp2H phenotype argues in favor of the tongue
defect being due to reduced Pax3 dosage rather than any non-
specific effects of neomycin itself.
Collectively, these observations indicate that an ∼80% loss
of Pax3 protein expression results in hypoplastic tongue muscle
formation and that the intrinsic musculature is especially
sensitive to reduced Pax3 levels. The hypoplastic tongue is
likely to result in the observed suckling defects as evidenced by
lack of ingested milk, which ultimately leads to Pax3neo/neo
neonatal growth retardation, wasting and lethality.
Reduced Pax3 levels also result in severe limb muscle
hypoplasia
Given that Pax3 nulls exhibit severe muscular hypoplasia
defects (Franz et al., 1993; Epstein et al., 1996; Engleka et al.,
2005), we next examined limb musculature at E13.5, E15.5 and
day 2; both before and after the undersized and warped forelimb
defects could be observed (Fig. 3A). As gross skeletal
abnormalities are invariably present in Pax3 mutants (Tremblay
et al., 1998; Dickman et al., 1999; Henderson et al., 1999), we
assessed whether reduced Pax3 expression can cause skeletal
malformations. Alizian red/Alizian blue staining revealed that
Pax3neo/neo skeletons are unaffected, except for occasional
fusion between the 1st and 2nd ribs (data not shown, n=3/10).
The skeletal system was otherwise indistinguishable between
Pax3neo/neo and littermates controls, and despite the subsequent
muscular defects, the size, proportion and positioning of each
limb bone and cartilage were normal (n=10 +/+ and Pax3neo/neo
E18 littermates). Analysis of MyoD expression in E15.5
forelimbs revealed that several MyoD-expressing muscle
masses present in control embryos were absent in Pax3neo/neo
limbs (Figs. 2C, E). Similarly, analysis of αSMA expression at
E13.5 supported the MyoD differences. αSMA staining re-
vealed that hypomorphic forelimb muscular masses were either
absent or significantly reduced in size prior to any gross defects
(Fig. 2F). Specifically, the more distal the muscle, the more
severe the hypoplasia, and dorsal extensor muscles were more
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also seen with Pax3neo/neo hindlimbs, albeit it was less grossly
dysmorphic (Fig. 2G). However, musculature of dorsal, ventral
and lateral body wall appeared grossly normal in Pax3neo/neo, as
evidenced viaMyoD and αSMA expression (Supplemental Fig.
2). Taken together, these observations indicate that the hypo-
morphic allele specifically affected skeletal limb musculature
derived from myoblast precursor cells that undergo medial–
lateral migration from the somitic dermomyotome.
Reduced Pax3 levels results in deficient migratory limb
myoblasts
In order to document if the hypomorphic reduction of Pax3
(as shown via RT-PCR and Western) globally affects all Pax3-
expressing cell lineages, we initially used in situ hybridization
to examine Pax3 spatiotemporal expression. In wild-type E10.5
embryos, Pax3 mRNAwas robustly expressed in the dorsal NT,
dorsal root ganglia, somites and limb bud in a pattern consistent
with published reports (Goulding et al., 1991; Conway et al.,
1997a). Specifically, Pax3-expressing cells in limb buds are
distributed along the dorsal and ventral sides of limb bud,
representing the migratory myoblasts (Fig. 4A). In contrast, in
E10.5 Pax3neo/neo limb buds, Pax3 expression was significantly
decreased, indicating a greatly reduced number of Pax3-ex-
pressing migrating myoblasts. Although reduced relative to
wild-type littermates, Pax3 was detectable in Pax3neo/neo dorsal
NT, dorsal root ganglia and somites in similar expression do-
mains as control littermates (Fig. 4B). We also performed in situ
hybridization targeting the 5′ and 3′ ends of Pax3mRNA and as
expected, both are appropriately co-expressed at low levels inFig. 4. Molecular marker analysis of migratory limb myoblasts and dorsal–ventral n
(A, B), cMet (C, D), Myf5 (E, F) and Msx2 (G, H) spatiotemporal expression pattern
expressed at reduced levels within Pax3neoo/neo (neo/neo) dorsal NT (arrow head), ad
hypomorphic limb buds apart from a few isolated myoblasts (B). The arrows indicate
cMetmRNA exhibits reduced expression in the Pax3neo/neo limb buds (arrow in panel
reduced in Pax3neo/neo limb buds (arrow in panel F) but is maintained in Pax3neo/neo so
limb apical ectodermal ridge (*) and body wall within both wild-type (G) and hypoPax3 target sites in hypomorphic embryos (data not shown),
indicating that insertion of the Neo gene does not result in
ectopic expression patterns. Next we examined downstream
targets such as c-Met and the myogenic target Myf5 in E10.5
limb buds. Pax3 is required for the activation of c-Met, a
receptor for HGF required for delamination and migration of
muscle progenitor cells (Bladt et al., 1995). c-Met is expressed
in cells migrating from the ventral lip of the dermomyotome and
present on both dorsal and ventral sides of the wild-type limb
buds but is largely absent in Pax3neo/neo limb buds (Fig. 4D),
and appears to be up-regulated in the somite itself. Similarly,
expression of Myf5 (an early marker of muscle differentiation;
Bajard et al., 2006) is also down-regulated in Pax3neo/neo limb
buds (Fig. 4F). These analyses indicate that it is an absence of
colonizing myoblasts rather than normal numbers of very low
Pax3-expressing myoblasts (i.e. below-detection via in situ
hybridization) that is the underlying cause of hypomorphic limb
muscle hypoplasia.
Reduced Pax3 levels do not affect dorsal-ventral neural tube
patterning
Given the extensive published data that link altered Pax3
expression to abnormal cardiac NC and subsequent outflow
tract remodeling (Conway et al., 1997a,b,c, 2000; Epstein et al.,
2000; Chan et al., 2004), altered dorso-ventral restricted Pax3
expression in the NT and resultant abnormal limb, eye, brain
and NT development (Tremblay et al., 1996) and defective
closure of the NT in Pax3-deficient embryos that can result in
spina bifida and/or exencephaly (Conway et al., 1997b; Pani
et al., 2002), we performed in situ hybridization with moleculareural tube patterning. Radioactive in situ hybridization was used to assess Pax3
s in E10 embryos. (A, B) In contrast to wild-type embryos (A), Pax3 mRNA is
jacent dorsal root ganglia, somites (som) and is mostly undetectable within the
the two Pax3-expressing populations missing in hypomorphic limb buds. (C, D)
D) when compared to wild-type (+/+ ) littermates (C). (E, F)Myf5mRNA is also
mites. (G, H)Msx2mRNA exhibits similar expression patterns in the dorsal NT,
morphic embryos (H). Arrowheads point to mid-NT boundary.
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genesis. Although expression of Crabp1 and Ap2α, both NC
markers, is diminished in the migratory cardiac NC in Pax3 null
embryos (Conway et al., 1997a, 2000), their expression is un-
altered in Pax3neo/neo embryos (Supplemental Fig. 1). Specifi-
cally, Crabp1 (which is expressed in NT, migratory NC and
dorsal root ganglia) exhibits similar ventral NT/floor plate ex-
clusion (Supplemental Figs. 1E, F). Ap2α (that is only ex-
pressed in normal emigrating NC; data not shown) is appro-
priately expressed in dorsal root ganglia and migrating NC.
Similarly, given that Msx2 is co-expressed with Pax3 in the
dorsal NT and is known to be repressed by Pax3 (Kwang et al.,
2002), we investigated whetherMsx2 expression was altered by
reduced Pax3 levels (Figs. 4G, H).Msx2 expression was normal
within E10.5 Pax3neo/neo dorsal NT, neuroectoderm and apical
ectodermal ridges that control limb bud outgrowth.
Apoptotic rates are specifically increased within Pax3neo/neo
somites
To determine the underlying mechanism responsible for the
hypoplastic limb and tongue muscle defects, we first investi-
gated whether reduced proliferation could account for the
reduced musculature. Using BrdU in vivo labeling, we found
the cell proliferation index was comparable between Pax3-
expressing and non-Pax3-expressing cells in both control and
Pax3neo/neo somites and limb buds at E10.5 (n=3 E10.5 em-
bryos of each genotype; data not shown), indicating that the
observed 80% reduction of Pax3 expression does not affect cell
proliferation. We then examined whether the hypoplastic mus-
cle defects may be due to excessive cell death. Using TUNEL,
we found there was a marked increase in E10.5 Pax3neo/neoFig. 5. Apoptotic rates are specifically increased within Pax3neo/neo somites. Apopto
serial transverse sections. Note that a significant proportion of the mesodermal cell
within the lateral edge of the dermomyotome that gives rise to the migratory limb mu
TUNEL-positive (A). Each arrow indicates a somite. However, the apoptotic index is
arrowheads in panels A and D). Similarly, the apoptotic index is comparable in wildsomitic cells undergoing apoptosis, when compared to wild-
type littermates (Fig. 5D). Significantly, increased apoptosis
was only detected within the somites and not within other
Pax3neo/neo tissues, including Pax3-expressing dorsal root
ganglia and NT (Fig. 5E). Similarly, increased apoptosis was
also observed in the E10.5 hypomorphic occipital myotomes
that give rise to the tongue muscles (data not shown), but
apoptosis was not elevated in E12.5 hypomorphic tongues (Fig.
5F). Furthermore, the TUNEL labeling index was not increased
in hypomorphic E10.5 limb buds (data not shown). The TUNEL
assays indicate that the muscular defect in limb and tongue was
not due to increased cell death during myoblasts, migration/
colonization but rather due to increased cell death of myoblast
progenitors prior to myoblasts emigration/colonization of the
mutant limb and tongue mesenchyme. This increased apoptosis
probably also underlies the observed mis-expression of hypo-
morphic somitic and migratory cell population markers. Histo-
logy revealed that early E9 and E10 hypomorphic somites ap-
pear to be normal and at appropriate developmental stages (data
not shown). This indicates that ∼20% Pax3 expression was not
sufficient to maintain cell survival specifically within the
somitic lineage. This analysis is consistent with previous reports
that Pax3 is essential for somitic survival and it is also required
for delamination and migration of myoblast progenitor cells
(Epstein et al., 2000; Buckingham et al., 2003).
Pax3 protein levels are uniformly reduced while Pax7 protein
levels are up-regulated in Pax3neo/neo embryos
As Pax3 reduction is a global phenomenon in Pax3neo/neo
embryos but the defects are not evident in all Pax3-expressing
lineages, we investigated whether Pax3 protein was globallytic cells were detected via TUNEL in wild-type (A–C) and Pax3neo/neo (D–F)
s of the E10.5 hypomorphic somites are undergoing apoptosis (D), specifically
scle precursors. In contrast, only a few E10.5 wild-type lateral somitic cells are
comparable in wild-type and Pax3neo/neo NT (B and E) and hindgut (indicated by
-type and Pax3neo/neo (arrow) E12.5 tongues (C and F).
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(Figs. 6A–H). Consistent with in situ hybridization analysis
(Figs. 4A, B), Pax3 was detected in E10.5 NT, somites and
proximal dorsal–lateral limb bud in wild-types. Specifically,
Pax3 was evenly distributed throughout the entire somite.
However, in Pax3neo/neo embryos, Pax3 protein is largely absent
in the dorsolateral somitic (hypaxial myotome) cells that are
destined to migrate into the limb bud to form muscles (Fig. 6E)
and from the occipital myotomes (data not shown). In E11.5
Pax3neo/neo dermomyotome, the lateral region is absent and thus
Pax3 expression is diminished (Fig. 6H). However, Pax3 is
spatiotemporally normally expressed in hypomorphic NT but is
down-regulated (Fig. 6F). Few, if any, Pax3-positive cells were
detected in E10.5 Pax3neo/neo limb bud (Fig. 6G).
Given Pax3 is most closely related to Pax7 and they repre-
sent a Pax subfamily (Buckingham and Relaix, 2006) and
during somitogenesis Pax7 is activated in the dermomyotome
after Pax3, but before the onset of expression of muscleFig. 6. Pax3 protein levels are uniformly reduced while Pax7 protein levels are up-re
(I–L) spatial expression and Western blot analysis (M) were used to assess relative Pa
the midline dorsal aorta (mdAo) region, Pax3 protein is present in all the mesodermal
at reduced levels and is almost absent within the dorsolateral portion (arrow in pan
hypomorphic NT (F) and is absent within the E10.5 forelimb buds (G) when compar
region is absent and thus Pax3 expression is diminished (H) when compared to contr
E10.5 somites (I) and restricted to the medial portion of the wild-type NT (J), but in co
into the dorsal region of the NT in Pax3neo/neo embryos (L, indicated by arrows). (M)W
(∼6-fold) in Pax3neo/neo embryos when compared to wild-type littermates, despite th
were reduced in Sp2H/Sp2H mutants when compared to wild-type littermates. Scale bregulatory factors (Jostes et al., 1990), we investigated whether
Pax7 protein is up-regulated in a cell lineage-specific manner
that could partially compensate for reduced Pax3 expression.
We checked Pax7 expression at E10.5 via immunohistochem-
istry and Western analysis using a Pax7-specific antibody (Figs.
6I–M). In wild-types, both somitic and dorsal NT expressions
were observed, but Pax7 expression was mainly restricted to the
medial NTwith the dorsal-most region being negative (Fig. 6J).
However, in Pax3neo/neo embryos, Pax7 was elevated in both
the somites and the NT (Figs. 6K, L). Additionally, Pax7-ex-
pressing zone was dorsally expanded in the NT. This up-
regulation of Pax7 was confirmed by Western analysis of E10.5
whole embryo lysates showing a ∼6-fold increase of Pax7
(densitometry analysis via ImageJ) in Pax3neo/neo embryos (Fig.
6M). In order to test whether up-regulation of Pax7 levels is
invariably a consequence of reduced Pax3 levels, Pax7 expres-
sion levels were analyzed via Western analysis of E10.5 Sp2H/
Sp2H embryos (Fig. 6M). Pax7 levels are not up-regulated butgulated in Pax3neo/neo hypomorphs. Immunodetection of Pax3 (A–H) and Pax7
x3 and Pax7 protein expression levels. In equivalent transverse sections through
cells of the concentric whorls of the E10.5 wild-type somites (A) but is expressed
el E) of the Pax3neo/neo somites. Pax3 expression is also reduced in the E10.5
ed to wild-type embryos (B, C). In E11.5 Pax3neo/neo dermomyotome, the lateral
ols (D). In adjacent sections, Pax7 protein is only weakly expressed in wild-type
ntrast Pax7 expression is elevated in the hypomorphic somites (K) and expanded
estern analysis of E10.5 whole embryos revealed that Pax7 levels were elevated
e actin loading control being expressed at similar levels. In contrast, Pax7 levels
ar in panel K=100 μm.
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are differentially modulated via reduced Pax3 levels as opposed
to absent Pax3.
Reduced Pax3 levels do not affect heart development
Given Pax3 null mutation results in PTA and associated VSD
(Auerbach, 1954; Franz, 1989; Conway et al., 1997a,b, 2003;
Engleka et al., 2005), the reduction of Pax3 expression and
neonatal death prompted us to investigate whether Pax3neo/neo
pups had heart defects. Both wholemount and histological
examinations of Pax3neo/neo hearts at E14.5, a stage at which
both ventricular septation and outflow tract division are
normally complete, reveal that Pax3neo/neo hearts are normal
(n=10). Specifically, separate aortic and pulmonary outlet
vessels are present, correctly aligned and exit the appropriate
ventricle, while the muscular and membranous interventricular
septum is closed. Furthermore, the thickness of ventricular and
atrial walls and ventricular septum also all appear unaffected by
reduced Pax3 levels (Supplemental Figs. 1A–D). Given that
100% of the Pax3neo/neo neonates die shortly after birth and the
presence of patent ductus arteriosus in partially rescued trans-
genic Sp homozygous newborns (Li et al., 1999), we also
analyzed the ability of the in utero Pax3neo/neo cardiovascular
system to adapt to postnatal requirements. Histology revealed
that the Pax3neo/neo ductus arteriosus and foramen ovale were
both closed within 6 h of birth (not shown), and thus the
Pax3neo/neo newborn pups were able to increase arterial oxygen
tension upon delivery, a process known to trigger closure of the
ductus arteriosus (Conway et al., 2003). Collectively, these
analyses demonstrated that Pax3neo/neo hearts were structurally
(and probably functionally) normal, given the healthy appear-
ance of the newborns and intact circulation (Fig. 3A).
The cardiac NC is known to be dependent upon Pax3 and be
required for normal outflow tract morphogenesis. Indeed, failure
of migration, proliferation, colonization and/or differentiation
can lead to pathogenesis of PTA and associated VSD (Conway et
al., 1997a,b; Snider et al., 2007). The normal outflow tract
morphogenesis observed in Pax3neo/neo suggests that either
cardiac NC cells are affected but are present in sufficient
numbers to support outflow tract septation or that the cardiac NC
lineage is unaffected by reduced Pax3 expression. To distinguish
which of these possibilities is present in Pax3neo/neo embryos,
we performed in situ hybridization to examine molecular mark-
ers of NC morphogenesis (Supplemental Figs. 1E–J). We have
previously shown that Crabp1 expression is unaltered in
Pax3neo/neo NT, and wholemount analysis reveals that there are
also an equivalent number and appropriate spatiotemporal mi-
gration route taken by Pax3neo/neo cardiac NC (data not shown).
Similarly, expression of Periostin (Supplemental Figs. 1G, H)
and Sox10 (Supplemental Figs. 1I, J), markers of differentiated
NC-derived outflow tract mesenchyme and Schwann cells,
respectively (Britsch et al., 2001; Lindsley et al., 2007), is
comparably expressed in Pax3neo/neo and wild-type dorsal root
ganglion and outflow tract. Thus, molecular marker analysis
indicates the cardiac NC lineage is unaffected by reduction of
Pax3 in Pax3neo/neo embryos.Diaphragmatic muscle morphogenesis tolerates reduced Pax3
levels
In vertebrates, all skeletal muscles are derived from the
paraxial mesoderm. Some muscle groups develop in situ, such
as the epaxial muscles of the trunk, which form the deep mus-
cles of the back. In contrast, several muscle groups derive from
cells that migrate over long distances as undifferentiated pre-
cursor myoblasts before undergoing myogenesis and fusing.
Hypaxial muscles including those of the limb, the ventral body
wall, the tongue and the diaphragm fall into this category
(Epstein et al., 1996; Schäfer and Braun, 1999; Buckingham et
al., 2003). Given the diaphragm is severely affected by various
Pax3 null mutations and its function is vital for postnatal
survival, we also analyzed potential effects of reduced Pax3
expression upon the Pax3neo/neo diaphragm using both histol-
ogy and immunohistochemistry. In contrast to the hypoplastic
diaphragm reported in Pax3 null mutants (Li et al., 1999;
Engleka et al., 2005), the Pax3neo/neo diaphragm is indis-
tinguishable from that of littermate controls with respect to its
appearance and thickness. Furthermore, immunostaining of
E15.5 differentiated myofibers using αSMA revealed that the
Pax3neo/neo diaphragm and ventral body wall were also indis-
tinguishable from that of controls, indicating they had appro-
priately undergone muscularization (Supplemental Fig. 2).
Similarly, the newborn diaphragm was normal (not shown).
To further document that the diaphragm was functionally
normal in Pax3neo/neo animals, we analyzed neonatal lungs
collected 6 h after delivery. The Pax3neo/neo and control litter-
mate lungs were also indistinguishable, with both genotypes
showing inflated and similar-sized alveoli (Supplemental Figs.
2C, F) indicating respiration had been initiated in Pax3neo/neo
animals. We next examinedMyoD expression at E15.5 by in situ
hybridization to assess whether MyoD is normally switched on.
Consistent with αSMA staining,MyoD is robustly expressed in
Pax3neo/neo intercostal muscles of the ventral body wall and
diaphragm with a similar intensity as wild-types (Supplemental
Figs. 2G, H). These analyses of the heart and diaphragm were
consistent with gross observation of Pax3neo/neo pups, which
exhibited a healthy coloration and a smooth rhythm of respi-
ration similar to their control littermates. Given Pax3neo/neo pups
did not appear cyanotic due to respiration failure or pale due to
compromised circulation. This suggests both their diaphragm
and cardiopulmonary systems are intact and functionally nor-
mal. Taken together, these analyses demonstrate that ∼20%
Pax3 protein was sufficient to initiate/maintain normal organo-
genesis of heart and diaphragm.
Discussion
Our analysis of the Pax3neo/neo hypomorphic defects clearly
indicates that long-range myoblast migration into the limb and
tongue is particularly sensitive to reduced Pax3 levels, but that
long-range myoblast migration to diaphragm, intercostal, body
wall and trunk is able to tolerate an 80% reduction in Pax3.
Furthermore, NT closure and NC-derived tissues and organs are
all also unaffected by reduced Pax3 expression, indicating that
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non-myogenic biological processes. Indeed, Pax3 dosage-
dependent anomalies have been observed for decades, as
heterozygous loss-of-function PAX3 mutation results in pig-
mentary disturbances in both mouse and human and cochlear
deafness in man (Tassabehji et al., 1992). These Pax3 mutant
data clearly indicate that a∼50% loss of Pax3 protein can affect
melanocytes and ear pigment cells. Given we can now further
titrate Pax3 expression levels, it is interesting to note that adult
Pax3neo/+ (∼60% Pax3 levels) mice do not exhibit any
pigmentation defects; however, further studies will be required
to test whether a ∼10% difference in Pax3 levels or potential
genetic background effects account for this intriguing result.
Although it is critically dependent upon Pax3 and the initial site
of Pax3 expression in the embryo (Goulding et al., 1994), the
dorsal neural folds/NT and NC lineages derived thereof, appear
to be unaffected by∼80% reduction in Pax3 levels. This clearly
establishes that there are different minimum threshold level
requirements for Pax3 among the various Pax3-expressing
lineages. Significantly, characterization of a Pax3-engrailed
fusion hypomorphic allele by Bajard et al. (2006) found a
similar attenuated mutant phenotype, with partial conservation
of the hypaxial somite and its myogenic derivatives, including
some hindlimb muscles and NT closure defects. However, the
Pax3-engrailed fusion hypomorphic allele does not lead to
extensive loss of myogenic progenitor cells in the hypaxial
somite, although the migration of these cells to the limb buds
was affected. This indicates that neomycin (acts via suppression
of Pax3 levels) and Pax3-engrailed fusion (acts via interference
of Pax3 function) alleles each result in overlapping but distinct
anomalies.
In terms of the myogenic defects, the titration of Pax3 ex-
pression levels down to ∼20% has revealed that Pax3-
expressing epaxial muscles are unaffected, and that only some
hypaxial-derived muscles are affected. As the hypaxial
musculatures (i.e. limb muscles, tongue, diaphragm, intercostal
and abdominal wall muscles) are all derived from ventrolateral
regions of the dermomyotome (Ordahl and Le Douarin, 1992;
Christ and Ordahl, 1995; Ordahl and Williams, 1998; Kablar
and Rudnicki, 2000), it is surprising that only the limb and
tongue muscles were hypoplastic. Furthermore, Pax3neo/neo
forelimb muscle hypoplasia is significantly more severe than
that observed in hindlimbs, and that dorsal limb muscle
hypoplasia is more severe than ventral limb muscle hypoplasia.
Significantly, localized muscle deficiencies in Pax3neo/neo can
be observed as early as E10.5 in the limb and E12.5 in cranio-
facial region. Underlying this muscle hypoplasia is an elevation
of apoptosis within E9.5–10.5 hypomorphic somites, that
results in a drastic reduction of long-range migratory progenitor
hypaxial myoblasts and consequently reduced colonization of
the limbs and tongue. Although we detected a significant in-
crease in apoptotic cells in Pax3neo/neo somites, we are unable to
demonstrate whether apoptosis is confined to distinct popula-
tions that would normally give rise to the specific affected
muscular masses in tongue and limbs. Further detailed mole-
cular marker analysis and lineage mapping studies will be re-
quired to address this possibility. As Pax3 is normally expressedin both dorsal and ventral colonizing myoblasts in both the fore-
and hindlimbs and the remaining hypomorphic tongue and
forelimb flexor muscle precursors switch on normal Myf5 and
MyoD expression, the Pax3neo/neo hypomorphic partial hypaxial
muscle defects may be due to (1) hypaxial muscles existing as
distinct muscle precursor cells, specified via different Pax3
expression levels; (2) hypaxial precursors depending on Pax3-
regulated lineage-specific environmental cues that require
different Pax3 thresholds; (3) dependence upon lineage-specific
positional signals; or there is (4) partial genetic compensation
via other Pax family members.
Similar to the Pax3neo/neo hypomorphic limb anomalies,
compound Eya1/2 mouse mutants exhibit more severe muscle
hypoplasia of the forelimbs than the hindlimbs (Grifone et al.,
2007). Eya1, Eya2 and Eya4 are all co-expressed with Pax3
during mouse somitogenesis at the limb level and are thought to
lie genetically upstream of Pax3 in the formation of ventro-
lateral dermomyotome hypaxial region. Additionally, a similar
spectrum of severe extensor muscle hypoplasia but normal
flexor muscles observed in Pax3neo/neo was reported in Lbx1h
null embryos that ectopically express Pax3 in migratory myo-
blasts, but not in malformed Lbx1h null limbs (Schäfer and
Braun, 1999). Indeed, both Lbx1 and Lbx1h mutants have
hypoplastic musculature in limbs, but the tongue and diaphragm
appear unaffected (Schäfer and Braun, 1999; Gross et al., 2000).
Lbx1h is specifically expressed in migrating muscle cells and is
thought to be a key regulator of muscle precursor cell migration
required for the acquisition of dorsal identities of forelimb
muscles. Combined, these data indicate that specification of the
various hypaxial muscle groups is probably dependent upon
coordinated and lineage-specific pathways that are differentially
sensitive to alterations in gene dosage.
As Pax3 is required for the activation of c-Met (Epstein et al.,
1996; Yang et al., 1996; Relaix et al., 2003), which is important
for delamination and migration of muscle progenitor cells
(Bladt et al., 1995), it is not surprising that c-Met mRNA
expression is diminished in the Pax3neo/neo limb buds. In fact,
c-Met nulls phenocopy the Sp2H/Sp2H mutant muscle defects
and exhibit a generalized loss of musculature in limb, tongue,
diaphragm and body wall (Bladt et al., 1995; Prunotto et al.,
2004). Although it is not known whether different Pax3 levels
can differentially activate c-Met and reduced levels of c-Met are
still detectable by RT-PCR in Pax3 mutant limb buds (Yang
et al., 1996), future lineage-restricted and temporally regulated
Pax3 deletion and assessment of c-Met expression are required
to test whether different Pax3 thresholds specify different Pax3-
dependent hypaxial subpopulations and/or whether c-Met is
able to respond differently to various Pax3 levels. Similarly,
although there are no data to suggest any differences in Pax3
expression between fore- and hindlimbs, it is known that limb-
specific expression of Pitx1, Tbx4 and Tbx5 regulates the deter-
mination of limb identity (Margulies et al., 2001). Thus, the
finding that forelimb muscles are more severely affected than
the hindlimb hypaxial muscles, may similarly reflect lineage-
specific positional signaling and/or that the forelimbs develop
earlier than hindlimbs and the existence of compensatory path-
ways in developmentally older embryos.
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members, of particular interest is the observation that Pax3 can
be partially replaced by Pax7 in the mouse (Relaix et al.,
2004). Specifically, Pax7 can substitute for Pax3 function in
dorsal NT, NC cell and somite development, but not in the
formation of muscles involving long-range migration of
muscle progenitor cells as these mutants die perinatally.
Similar to the Pax3neo/neo hypomorph, the severity of the
limb muscle phenotype increases as the number of Pax7
replacement alleles is reduced, with the hypomorphic forelimb
more affected than the hindlimb (Relaix et al., 2004).
Expression studies have shown that Pax7 is not expressed in
myoblasts migrating from the occipital trunk somites to the
tongue primordium and is not expressed in limb myoblasts
until E11.5 as the limb muscles develop (Jostes et al., 1990;
Relaix et al., 2004; Horst et al., 2006). Thus, elevated Pax7
would not be able to compensate for reduced Pax3 levels in
these specific hypaxial lineages. However, in the myoblasts
that migrate to the septum transversum (which partly gives rise
to the diaphragm), Pax3 and Pax7 are co-expressed during
myoblast migration (Gross et al., 2000). Thus, the defects
observed in Pax3neo/neo intrinsic tongue muscles and limb
musculature, but not in the diaphragm and trunk, most likely
reflect the fact that Pax7 co-expression and up-regulation can
compensate for 80% reduction in Pax3 levels and rescue the
myoblasts that colonize the diaphragm. Given that Pax7 can
prevent apoptosis (Borycki et al., 1999; Kassar-Duchossoy et
al., 2005), these data could suggest that compensatory Pax7
up-regulation in Pax3neo/neo may be sufficient to overcome
commitment to the apoptotic pathway. The lack of Pax3neo/neo
NT and NC-associated anomalies most likely reflects that these
Pax3-expressing lineages are “rescued” via the compensatory
up-regulation of Pax7 within the dorsal NT. Thus, the limited
lineage-restricted hypomorphic defects observed in Pax3neo/neo
embryos reflect those tissues in which spatiotemporally
coordinated Pax7 up-regulation is not able to compensate for
80% reduced Pax3 dosage levels.
Taken together, the similarities in Pax3 and Pax7 expres-
sion, structure and function suggest that, while the two gene
products perform distinct functions, there is overlap. Future
conditional Pax3 and Pax7 deletion and compound mutational
studies will be required to dissect their relative roles during
myogenesis.
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